ClinicalTrials.gg
CompletedNCT07303907Updated Nov 13, 2026

A Phase 2A Trial of DT402 for Autism Spectrum Disorder

A Phase 2 interventional study of DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) in Autism Spectrum Disorder and ASD, sponsored by Definium Therapeutics US, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Definium Therapeutics US, Inc. · Phase 2, Interventional, and Treatment

Updated Nov 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 773 studies in Autism Spectrum Disorder with a site in United States — 165 open to participants now, 204 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.

Enrollment
619th of 658
5 · median 50
Started
2025
with 31 others
Phase 2
101 of 773
15 open now
Registered
737th of 773
by date

Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 619th largest by enrollment of the 658 interventional ones that give a count, is one of 32 that started in 2025, is one of 101 in phase 2, and was the 737th registered.

Autism Spectrum Disorder

1,729 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

165 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:

160 more — sign in →

All 165 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 300 take children under 18; 92 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 773 studies in Autism Spectrum Disorder with a site in United States, or all of them as a file.
02

Study summary

A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder

Read the detailed description

This study will enroll approximately twenty adults with Autism Spectrum Disorder (ASD) aged 18 to 65 years of age.

This is a multi-center, open-label study to evaluate the effects after a single administration of DT402 to adults with ASD.

03

Conditions studied

  • Autism Spectrum Disorder
  • ASD
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of ASD per records as confirmed by standard semi-structured interview for Autism diagnosis (eg, Autism Diagnostic Observation Schedule-Second Edition)
  2. Male or Female aged 18 to 65
  3. Presents with deficits in socialization and communication as determined by Social Responsiveness Scales (SRS-2) ≥66

Exclusion criteria

Exclusion Criteria:

  1. Has uncorrected abnormalities in eye movement, alignment, or acuity or atypical eye features that could interfere with eye tracking
  2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
  3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
  4. Any unstable illness
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    200 mg DT402

    A psychoactive substance that mediates effects mainly through a release of the monoaminergic neurotransmitters, with the greatest effect on 5-HT, followed by NE and DA

    Drug: DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline in 11-point Numerical Rating Scale (NRS) scores

    The NRS is an 11-point PRO scale used to measure the severity or intensity of effects from 0 (no effect) to 10 (high severity or intensity of effect). It consists of various items related to both positive and negative effects in the autism patient population.

    Time frame: Baseline, pre-dose and 2, 4, 6, 8, and 24 hours post-dose and day 15

Secondary outcomes

  1. Subjective 5-question Drug Effects Questionnaire (DEQ) scores

    The Drug Effects Questionnaire is used in studies to assess the participant's acute subjective effects after ingesting substances. It consists of 5 PRO items. The analog scale of responses ranges from "not at all" to "extremely." The score is determined by the distance between the left anchor point and the participant's mark on the line. Each item is scored separately.

    Time frame: 1, 2, 4, 6, 8, and 24 hours post-dose

  2. Pharmacokinetic Plasma concentrations

    Maximum Plasma Concentration \[Cmax\] of DT402 in the blood.

    Time frame: pre-dose and 1, 2, 4, 6, 8, and 24 hours post-dose

  3. Pharmacokinetic Parameters (Cmax)

    Maximum concentration (Cmax).

    Time frame: pre-dose and 1, 2, 4, 6, 8, and 24 hours post-dose

  4. Pharmacokinetic Parameters (Tmax)

    Time to maximum concentration (Tmax).

    Time frame: pre-dose and 1, 2, 4, 6, 8, and 24 hours post-dose

  5. Pharmacokinetic Parameters (t1/2)

    Time to maximum concentration half-life (t1/2).

    Time frame: pre-dose and 1, 2, 4, 6, 8, and 24 hours post-dose

  6. Pharmacokinetic Parameters (AUC0-inf)

    Area under the concentration curve from time 0 to infinity (AUC0-inf).

    Time frame: pre-dose and 1, 2, 4, 6, 8, and 24 hours post-dose

  7. Pharmacokinetic Parameters (AUC0-24h)

    Area under the concentration curve from time 0 to 24 hour (AUC0-24h).

    Time frame: pre-dose and 1, 2, 4, 6, 8, and 24 hours post-dose

07

Study locations

1 site
  • Spectrum Neuroscience and Treatment Institute
    New York, New York 10021, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2025 to primary completion in Sep 2026, 9 months.

Of 82 phase 2 interventional studies under Autism Spectrum Disorder, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 52. This study's 9 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Aug 2027 → Sep 2026 and completion Aug 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Dec 26, 2025
StartActual
Dec 3, 2025
Primary completionActual
Sep 16, 2026was Aug 2027
CompletionActual
Sep 16, 2026was Aug 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 13, 2026
Primary completion
Aug 2027→Sep 16, 2026 (actual)
Nov 13, 2026
Study completion
Aug 2027→Sep 16, 2026 (actual)
Nov 13, 2026
Enrollment
20 (estimated)→5 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Completed
    Primary completion Aug 2027→Sep 16, 2026 (now actual)
    Study completion Aug 2027→Sep 16, 2026 (now actual)
    Enrollment 20 (estimated)→5 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07303907
Lead sponsor
Definium Therapeutics US, Inc.
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Dec 3, 2025
Primary completion
Sep 16, 2026
Completion
Sep 16, 2026
Last update
Nov 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion